Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Psilocybin Cancer Anxiety Study
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 29
- Registration Number
- NCT00957359
- Locations
- 🇺🇸
NYU College of Dentistry Bluestone Center for Clinical Research, New York, New York, United States
Psilocybin and Spiritual Practice
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 75
- Registration Number
- NCT00802282
- Locations
- 🇺🇸
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Psychopharmacology of Psilocybin in Cancer Patients
- First Posted Date
- 2007-04-25
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 56
- Registration Number
- NCT00465595
- Locations
- 🇺🇸
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath